Basic Investigation| Volume 364, ISSUE 4, P454-460, October 2022

CircRNA circ-MYBL2 absorbs precursor miR-92b in the nucleus to suppress its role in enhancing gastric cancer cell proliferation

  • Ruijie Luo
    Correspondence author at: Ruijie Luo, Department of Critical Care Medicine, Chengdu Wenjiang District People's Hospital, No. 86 Kangtai Road, Wenjiang District, Chengdu, Sichuan, China
    Department of Critical Care Medicine, Chengdu Wenjiang District People's Hospital, Chengdu City, Sichuan, China
    Search for articles by this author



      MM-associated circular RNA (Circ-MYBL2), a circular RNA (circRNA), participates in cancer biology. However, its role in gastric cancer (GC) is unclear. In this study, circ-MYBL2 was predicted to interact with precursor microRNA-92b (miR-92b). We then analyzed the role of circ-MYBL2 in GC and explored its crosstalk with miR-92b.


      In this research Circ-MYBL2 and miR-92b (mature and precursor) accumulation was determined using reverse transcription polymerase chain reaction (RT-qPCR). The involvement of circ-MYBL2 in the maturation of miR-92b was analyzed using overexpression assays. The subcellular location of circ-MYBL2 was determined using nuclear fractionation assay. The binding of precursor miR-92b to circ-MYBL2 was analyzed through RNA-RNA pulldown assay. The role of circ-MYBL2 and miR-92b in GC cell proliferation was studied with BrdU assay.


      We found that GC tissues exhibited increased mature miR-92b levels but decreased precursor miR-92b and circ-MYBL2 levels. Circ-MYBL2 was detected in both the nucleus and cytoplasm in GC cells, and it directly interacted with precursor miR-92b. Moreover, circ-MYBL2 overexpression increased precursor miR-92b expression and decreased mature miR-92b level. Furthermore, miR-92b (mature) increased GC cell proliferation, and circ-MYBL2 decreased GC cell proliferation and suppressed the effect of miR-92b on GC cell proliferation.


      Circ-MYBL2 may absorb precursor miR-92b in the nucleus to suppress its role in promoting gastric cancer cell proliferation.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Van Cutsem E
        • Sagaert X
        • Topal B
        • et al.
        Gastric cancer.
        Lancet. 2016; 388: 2654-2664
        • Thrift AP
        • El-Serag HB.
        Burden of gastric cancer.
        Clinic Gastroenterol Hepatol. 2020; 18: 534-542
        • Rajappa A
        • Banerjee S
        • Sharma V
        • et al.
        Circular RNAs: emerging role in cancer diagnostics and therapeutics.
        Front Mol Biosci. 2020; 7577938
        • Orditura M
        • Galizia G
        • Sforza V
        • et al.
        Treatment of gastric cancer.
        World J Gastroenterol. 2014; 20: 1635-1649
        • Sitarz R
        • Skierucha M
        • Mielko J
        • et al.
        Gastric cancer: epidemiology, prevention, classification, and treatment.
        Cancer Manag Res. 2018; 10: 239-248
        • Kanaji S
        • Suzuki S
        • Matsuda Y
        • et al.
        Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer.
        Ann Gastroenterol Surg. 2018; 2: 400-405
        • Mokadem I
        • Dijksterhuis WPM
        • van Putten M
        • et al.
        Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
        Gastr Cancer. 2019; 22: 1263-1273
        • Ito S
        • Ohashi Y
        • Sasako M.
        Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
        BMC Cancer. 2018; 18: 449
        • Bencivenga M
        • Verlato G
        • Han DS
        • et al.
        Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer.
        Br J Surg. 2017; 104: 1235-1243
        • Shenoy S.
        CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management.
        Cancer Manag Res. 2019; 11: 10477-10486
        • Montenegro RC
        • Howarth A
        • Ceroni A
        • et al.
        Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib.
        Oncotarget. 2020; 11: 535-549
        • Astudillo P.
        Wnt5a signaling in gastric cancer.
        Front Cell Dev Biol. 2020; 8: 110
        • Meric-Bernstam F
        • Johnson AM
        • Dumbrava EEI
        • et al.
        Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer.
        Clin Cancer Res. 2019; 25: 2033-2041
        • Shang Q
        • Yang Z
        • Jia R
        • et al.
        The novel roles of circRNAs in human cancer.
        Mol Cancer. 2019; 18: 6
        • Yin Y
        • Long J
        • He Q
        • et al.
        Emerging roles of circRNA in formation and progression of cancer.
        J Cancer. 2019; 10: 5015-5021
        • Lu Y
        • Li K
        • Gao Y
        • et al.
        CircRNAs in gastric cancer: current research and potential clinical implications.
        FEBS Lett. 2021; 595: 2644-2654
        • Wang G
        • Sun D
        • Li W
        • et al.
        CircRNA_100290 promotes GC cell proliferation and invasion via the miR-29b-3p/ITGA11 axis and is regulated by EIF4A3.
        Cancer Cell Int. 2021; 21: 324
        • Zhang X
        • Wang S
        • Wang H
        • et al.
        Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway.
        Mol Cancer. 2019; 18: 20
        • Yu S
        • Ai L
        • Wei W
        • et al.
        circRNA circ-MYBL2 is a novel tumor suppressor and potential biomarker in multiple myeloma.
        Hum Cell. 2021; 34: 219-228
        • Wang J
        • Li H
        • Liang Z.
        circ-MYBL2 serves as a sponge for miR-361-3p promoting cervical cancer cells proliferation and invasion.
        Onco Targets Ther. 2019; 12: 9957-9964
        • Ni QF
        • Zhang Y
        • Yu JW
        • et al.
        miR-92b promotes gastric cancer growth by activating the DAB2IP-mediated PI3K/AKT signalling pathway.
        Cell Prolif. 2020; 53: e12630
        • Liu F
        • Sang M
        • Meng L
        • et al.
        miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
        Int J Oncol. 2018; 53: 1505-1515